No Data
WuXi XDC and LigaChem Biosciences Strengthen Partnership With Expanded MOU to Accelerate ADC Development
WUXI XDC signed a cooperation memorandum with LigaChem Biosciences to accelerate ADC development.
Shanghai, February 25, 2025 /PR Newswire/ -- WUXI XDC (stock code: 2268.HK), a global leader focused on providing end-to-end CRDMO services for bioconjugates such as antibody-drug conjugates (ADC), announced today the signing of a Memorandum of Understanding (MOU) with LigaChem Biosciences. LigaChem Biosciences is an industry pioneer in developing ADC therapies to tackle cancer and other major diseases, and the signing of this new agreement signifies further collaboration between the two parties.
Is Trump’s risk disturbing the market? Pharmaceutical stocks have suddenly changed, and the WuXi group has collapsed entirely!
Under the AI boom, the Biomedical and AI Medical stocks have been running wild this year.
Nomura Adjusts WuXi XDC Cayman's Price Target to HK$42.50 From HK$34.11, Keeps at Buy
Nomura: Maintain WUXI XDC (02268) "Buy" rating, raise Target Price to 42.5 HKD.
The organization maintains its previous forecast for WUXI XDC (02268) for the financial years 2024 and 2025, indicating that it expects the company's revenue and net profit in the second half of the 2024 financial year to grow by 54% and 255% year-on-year, respectively.
China Merchants: The surge in ADC research and development is driving a significant increase in outsourcing demand, and the ADC CDMO market is thriving.
The surge in ADC research and development has driven a significant increase in outsourcing demand, with strong market demand for ADC CDMO. Currently, the market shows a dual drive of capacity expansion and technological iteration.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}